Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.32 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: metformin, me-344, metformin hydrochloride | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 17 Parkinson's papers of 170 | 0.62 |
| pathways Reactome | 4 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 1090
Sealed predictions
- NDUFS3 in dopamine neurons, braak-0.64 (p 0.063) → +0.16 (p 0.685)receipt 1096
Swarm cases
receipt 1096: NDUFS3 in dopamine neurons, braak
- power
- full sample -0.08 (p 0.767, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.09 (p 0.722, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.10 (p 0.696, n 18). could be the mix.
- skeptic
- leave-one-out range -0.21 to +0.07, sign flips 1; without severely affected donors -0.08 (p 0.767, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NDUFS3 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts